Global Startups Insights
Lets your startup
Funding News, New York, USA Startup Funding News

Biotia Raises New Oversubscribed $9M Financing

October 1, 2026
By
Loren Baker
Biotia Raises New Oversubscribed $9M Financing

Biotia, a New York City-based clinical metagenomics company, has raised $9 million in an oversubscribed financing round to expand its diagnostic technology and laboratory operations.

The financing includes existing investors and comes after the company’s previously announced Series A. Investors participating in the round include Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels, and Red Bear Ventures, among others.

Biotia plans to use the new funding to expand its New York City laboratory, develop additional diagnostics for women’s health, and enter the orthopedic diagnostics market.

“This funding enables us to do what matters most: expand advanced diagnostics available for patients suffering from chronic infections who have been failed by standard laboratory methods,” said Niamh O’Hara, PhD, CEO and cofounder of Biotia. “We are using this capital to expand our test menu, pursue reimbursement, and get these tools into the hands of clinicians — so that more patients get better and faster answers. We are grateful to work every day with strong investors, advisors, and partners transforming how infectious diseases are diagnosed and understood.”

The company’s flagship BIOTIA-ID Urine Test is designed to identify the causes of recurrent and complicated urinary tract infections (UTIs). Biotia reports that the test has 97% sensitivity and 99% specificity and is available to physicians and patients across all 50 U.S. states.

Biotia combines pathogen genomics and artificial intelligence to develop diagnostic tools for challenging and chronic infections. The company operates a high-complexity, CLIA-certified diagnostic laboratory in New York City.

Alongside the new funding, Biotia has expanded its board and advisory team with healthcare and diagnostics professionals. Michele Colucci, CEO of DigitalDx Ventures, has joined as board chair, while Tim Barry, co-founder of VillageMD, has joined the board.

“Diagnostics are the foundation of better patient care, since you cannot manage what you cannot accurately measure. Biotia’s approach to precision infectious disease testing, especially their work in women’s health, is exactly the kind of innovation that improves outcomes while reducing unnecessary costs in the system. I’m excited to join the board and help Biotia scale,” said Mr. Barry.

“The esteemed leaders supporting Biotia at this stage are a testament to the importance of what we are building as we work to make clinical metagenomic solutions rapidly accessible for patients,” said Chris Mason, PhD, global director and cofounder of Biotia. “Their experience and perspective will be invaluable to accelerate our next phase of growth, expand our diagnostic applications to new markets, and help more patients.”

The company has also added healthcare and women’s health specialists to its advisory group as it prepares to expand its diagnostic portfolio.

Biotia is a spinout of the Jacobs Technion-Cornell Institute at Cornell Tech and has partnerships and collaborations with organizations including Mayo Clinic, Hospital for Special Surgery (HSS), and NASA.

Recommended Stories for You